William (Bill) Collier
Arbutus Biopharma
President and CEO


Bill is currently President and CEO, and a member of the board at Arbutus Biopharma, a NASDAQ-listed biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.

Since December 2018, Bill has been a board director of the International Partnership for Microbicides. Bill also served as a board director of AIDS United from 2011 to 2018 and as a member of President Obama’s Presidential Advisory Council on HIV/AIDS (PACHA) from 2014 to 2017. Bill is a member of the National Association of Corporate Directors (NACD).

Bill previously worked at ViiV Healthcare, a company focused uniquely on innovation in HIV treatment and education. Bill was President of ViiV Healthcare North America responsible for the multi-billion-dollar business operations in the US, Puerto Rico and Canada. Previously, Bill held several senior commercial roles for GlaxoSmithKline in the USA including Senior Vice President for Sales and Senior Vice President for Marketing Analytics and Commercial Operations. Bill gained a BSc honors in mathematics and management sciences from the University of Manchester, UK, and has completed leadership programs at the London Business School, INSEAD and Duke University.